[
  {
    "ts": null,
    "headline": "Pfizer (PFE) Outperforms Broader Market: What You Need to Know",
    "summary": "Pfizer (PFE) closed the most recent trading day at $25.9, moving +1.49% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=5a2511be82f9dd33a499a76f04f3c2335320026a358481f9481cd56c44cdedc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769035503,
      "headline": "Pfizer (PFE) Outperforms Broader Market: What You Need to Know",
      "id": 138200231,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) closed the most recent trading day at $25.9, moving +1.49% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=5a2511be82f9dd33a499a76f04f3c2335320026a358481f9481cd56c44cdedc7"
    }
  },
  {
    "ts": null,
    "headline": "Why Are Novavax (NVAX) Shares Soaring Today",
    "summary": "Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M adjuvant technology.",
    "url": "https://finnhub.io/api/news?id=9b483ea41f4d0dcd4b543da4b6dd9960cf51e7088679cf53f25ffbdc1a2c00dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769028050,
      "headline": "Why Are Novavax (NVAX) Shares Soaring Today",
      "id": 138199008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company announced it entered into a license agreement with Pfizer for its Matrix-M adjuvant technology.",
      "url": "https://finnhub.io/api/news?id=9b483ea41f4d0dcd4b543da4b6dd9960cf51e7088679cf53f25ffbdc1a2c00dc"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=11e2f38f97d7a1b4e771501a6b7bcd47d6f4d550358c26a0f5329fc722a68ca3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769013360,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 138209704,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=11e2f38f97d7a1b4e771501a6b7bcd47d6f4d550358c26a0f5329fc722a68ca3"
    }
  },
  {
    "ts": null,
    "headline": "Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer",
    "summary": "NVAX inks a non-exclusive Matrix-M license, securing $30M upfront, up to $500M in milestones and mid-single-digit royalties from Pfizer.",
    "url": "https://finnhub.io/api/news?id=98c82c000d49e6a4336b006b02cc88986a27182340f5429fe1b25b2607b9cece",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769007960,
      "headline": "Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer",
      "id": 138197259,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NVAX inks a non-exclusive Matrix-M license, securing $30M upfront, up to $500M in milestones and mid-single-digit royalties from Pfizer.",
      "url": "https://finnhub.io/api/news?id=98c82c000d49e6a4336b006b02cc88986a27182340f5429fe1b25b2607b9cece"
    }
  },
  {
    "ts": null,
    "headline": "Albert Bourla on the State of Pharma",
    "summary": "The Pfizer chief executive discusses his unexpected diplomatic role with world leaders during the pandemic, China's rapid pharmaceutical innovation rise, and his working relationship with vaccine-skeptic RFK Jr.",
    "url": "https://finnhub.io/api/news?id=bd9fff888e845e5450936ce5305e835fa5eeb4c97244dbb5f8c794931a9f69d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769006340,
      "headline": "Albert Bourla on the State of Pharma",
      "id": 138196104,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Pfizer chief executive discusses his unexpected diplomatic role with world leaders during the pandemic, China's rapid pharmaceutical innovation rise, and his working relationship with vaccine-skeptic RFK Jr.",
      "url": "https://finnhub.io/api/news?id=bd9fff888e845e5450936ce5305e835fa5eeb4c97244dbb5f8c794931a9f69d2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer CEO on His Relationship With RFK Jr.",
    "summary": "At WSJ Journal House in Davos, Albert Bourla describes how discussions with the U.S. Secretary of Health and Human Services change when it comes to vaccines.",
    "url": "https://finnhub.io/api/news?id=74fd39b12312d8533a7ebd772f947a5c2ab590199068e3efb9efde6867221b69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769001960,
      "headline": "Pfizer CEO on His Relationship With RFK Jr.",
      "id": 138195178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "At WSJ Journal House in Davos, Albert Bourla describes how discussions with the U.S. Secretary of Health and Human Services change when it comes to vaccines.",
      "url": "https://finnhub.io/api/news?id=74fd39b12312d8533a7ebd772f947a5c2ab590199068e3efb9efde6867221b69"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention",
    "summary": "TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.",
    "url": "https://finnhub.io/api/news?id=bf0184a33704a886bb1a71173c5fd3cd56e28e51abc7289f5d4462544a0a9d31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769000220,
      "headline": "Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention",
      "id": 138196025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.",
      "url": "https://finnhub.io/api/news?id=bf0184a33704a886bb1a71173c5fd3cd56e28e51abc7289f5d4462544a0a9d31"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and Novavax ink $530m vaccine delivery licensing deal",
    "summary": "Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.",
    "url": "https://finnhub.io/api/news?id=859334bc7b266078d39cd2cfbf8d56ee2e068ec7ffd0660aa7257427495649eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768998302,
      "headline": "Pfizer and Novavax ink $530m vaccine delivery licensing deal",
      "id": 138195179,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.",
      "url": "https://finnhub.io/api/news?id=859334bc7b266078d39cd2cfbf8d56ee2e068ec7ffd0660aa7257427495649eb"
    }
  },
  {
    "ts": null,
    "headline": "3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer",
    "summary": "One of these suggested stocks features a dividend yield topping 10%.",
    "url": "https://finnhub.io/api/news?id=f627b191f0240090b47018b5cccf1e815a27a965747c80ef6932034c03bc3a74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768995960,
      "headline": "3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer",
      "id": 138194418,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "One of these suggested stocks features a dividend yield topping 10%.",
      "url": "https://finnhub.io/api/news?id=f627b191f0240090b47018b5cccf1e815a27a965747c80ef6932034c03bc3a74"
    }
  },
  {
    "ts": null,
    "headline": "Trump at Davos, Intel Earnings, Supreme Court: What to Watch This Week",
    "summary": "Earnings season kicked up a gear this week, with results still due from Johnson & Johnson and Intel, among other companies. Plus, President Trump is at the World Economic Forum in Davos, Switzerland, where he is due to speak on Wednesday.",
    "url": "https://finnhub.io/api/news?id=5fd00ce9a9e7ae53d50b687acaca8ce78ff8a1c19f7115fb4c2c0ea093f9a38d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768986391,
      "headline": "Trump at Davos, Intel Earnings, Supreme Court: What to Watch This Week",
      "id": 138194305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Earnings season kicked up a gear this week, with results still due from Johnson & Johnson and Intel, among other companies. Plus, President Trump is at the World Economic Forum in Davos, Switzerland, where he is due to speak on Wednesday.",
      "url": "https://finnhub.io/api/news?id=5fd00ce9a9e7ae53d50b687acaca8ce78ff8a1c19f7115fb4c2c0ea093f9a38d"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M",
    "summary": "Novavaxâs Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=860406908a721d94f9a2fd15d2f74969be9b364086471eb4f6e839afb4758159",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768985160,
      "headline": "Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M",
      "id": 138195202,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1339385973/image_1339385973.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Novavaxâs Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=860406908a721d94f9a2fd15d2f74969be9b364086471eb4f6e839afb4758159"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns",
    "summary": "If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will walk through what the numbers actually say about the stock. Pfizer's share price recently closed at US$25.52, with returns of 1.5% over 7 days, 1.3% over 30 days, 1.4% year to date and 2.7% over 1 year, set against a 32.1% decline over 3 years and a 12.7% decline over 5 years. Recent attention on Pfizer has focused on how the business is positioned after the initial...",
    "url": "https://finnhub.io/api/news?id=6dcce9e03dce2b7079cdb8c2b9fe27c1bbabbf712cff3a8b88a4bf81d56c2976",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768965535,
      "headline": "Is Pfizer (PFE) Pricing Make Sense After Post Covid Slowdown Concerns",
      "id": 138192114,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will walk through what the numbers actually say about the stock. Pfizer's share price recently closed at US$25.52, with returns of 1.5% over 7 days, 1.3% over 30 days, 1.4% year to date and 2.7% over 1 year, set against a 32.1% decline over 3 years and a 12.7% decline over 5 years. Recent attention on Pfizer has focused on how the business is positioned after the initial...",
      "url": "https://finnhub.io/api/news?id=6dcce9e03dce2b7079cdb8c2b9fe27c1bbabbf712cff3a8b88a4bf81d56c2976"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Novavax (NVAX) Valuation After Pfizer Matrix M Licensing Deal",
    "summary": "Novavax (NVAX) has become a focus for investors after signing a license agreement that allows Pfizer to use its Matrix-M adjuvant in up to two disease areas, with upfront, milestone, and royalty payments included. See our latest analysis for Novavax. The Matrix M agreement and Novavax’s upcoming appearance at the J.P. Morgan Healthcare Conference come after a 23.1% 1 month share price return to US$8.20. However, the 1 year total shareholder return of a 6.9% decline and the 5 year total...",
    "url": "https://finnhub.io/api/news?id=fddef8f677214e1ac301873ae8be3992522827a8162c12eeef26d380a17193bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768965330,
      "headline": "Assessing Novavax (NVAX) Valuation After Pfizer Matrix M Licensing Deal",
      "id": 138192115,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Novavax (NVAX) has become a focus for investors after signing a license agreement that allows Pfizer to use its Matrix-M adjuvant in up to two disease areas, with upfront, milestone, and royalty payments included. See our latest analysis for Novavax. The Matrix M agreement and Novavax’s upcoming appearance at the J.P. Morgan Healthcare Conference come after a 23.1% 1 month share price return to US$8.20. However, the 1 year total shareholder return of a 6.9% decline and the 5 year total...",
      "url": "https://finnhub.io/api/news?id=fddef8f677214e1ac301873ae8be3992522827a8162c12eeef26d380a17193bf"
    }
  }
]